Breast Cancer

For patients with early HR-positive, HER2-positive breast cancer who initiated neratinib within 1 year of completing trastuzumab and in patients who did not achieve a pathologic complete response after neoadjuvant treatment, neratinib may be a cost-effective treatment option.

Participation in certified educational activities resulted in significant improvements in knowledge, competence, and confidence regarding the use of CDK4/6 inhibitor therapies in the management of patients with advanced HR-positive breast cancer.

The combination of exemestane and entinostat did not show survival benefit in patients with aromatase inhibitor–resistant, HR-positive, HER2-negative advanced breast cancer.

Subgroup analysis of the phase 3b CompLEEment-1 clinical trial supports the use of ribociclib combined with letrozole in HR-positive, HER2-negative advanced breast cancer male patients based on demonstrated efficacy and safety.

In a predominantly black, low-income population, women with diabetes and incident localized breast cancer had decreased overall survival when compared with those without diabetes.

Subgroup analysis of the phase 3b CompLEEment-1 clinical trial reinforces the efficacy and safety of ribociclib plus letrozole in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.

An alternative schedule of palbociclib reduced grade ≥3 neutropenia and showed efficacy data comparable with previous reports.

Findings from this study show that based on the adjusted adherence rate of the combination therapy of exemestane and everolimus, a low-rate adherence was observed.

Consistent with previous phase 3 studies with ribociclib and letrozole, few patients with HR-positive, HER2-negative advanced breast cancer and central nervous system metastases discontinued treatment due to side effects.

Do you recognize the barriers to care that women of racial minorities face? There may be more than you realize.